Activating mutations in the RET proto-oncogene are associated with both familial and sporadic medullary thyroid carcinoma (MTC) development; however, the genetic mechanisms underlying MTC tumorigenesis remain largely unknown. Recently, we have identified somatic inactivating mutations in the cell cycle inhibitor gene P18 in human MTC, which coincided with activating RET mutations, suggesting a role for loss of P18 in combination with oncogenic RET in the multistep process of MTC development. Therefore, we crossed transgenic mice expressing oncogenic RET (RET2B) with mice lacking p18 (and p27, another cell cycle inhibitor) and monitored MTC development. RET2B;p18 +/À mice and RET2B;p18 À/À mice developed MTC with a highly increased incidence compared with their corresponding single mutant littermates. In addition, expression of oncogenic RET causes an earlier age of onset and larger MTCs in p18;p27 +/À mice. In a subset of MTCs of RET2B;p18Ink4c expression was completely lost. This loss of p18 Ink4c expression correlated with higher proliferation rates as well as with larger MTCs, indicating that loss of p18 in combination with oncogenic RET not only increases the risk for MTC development but also enhances MTC progression. Our data strongly indicate that oncogenic RET and loss of p18 cooperate in the multistep tumorigenesis of MTC. [Cancer Res 2008;68(5):1329-37]
In multiple endocrine neoplasia syndrome Type 2 (MEN2), medullary thyroid carcinoma (MTC) and pheochromocytoma (PC) are associated with hereditary activating germ-line mutations in the RET proto-oncogene. Also in a large percentage of sporadic MTCs and PCs, somatic RET mutations appear to be involved in tumor formation. In one single MEN2 family an extensive variety in disease expression may be observed, indicating that additional genetic events are responsible for progression of the disease towards a more aggressive phenotype. However, these additional mutations in both hereditary and sporadic MTC and PC development are largely unknown. Here, we show for the first time the presence of somatic mutations in the cell cycle regulator P18 in human RET-associated MTCs and PCs. Each of these mutations causes an amino acid substitution in the cyclin dependent kinaseinteracting region of P18 INK4C . Since these mutations partly inhibited P18 INK4C function and reduced its stability, our findings implicate P18 as a tumor suppressor gene involved in human MTC and PC development. ' 2008 Wiley-Liss, Inc.Key words: P18 INK4C; medullary thyroid carcinoma; RET; tumor suppressor gene; multistep tumorigenesis Multiple endocrine neoplasia Type 2 (MEN2) is an autosomal dominantly inherited cancer syndrome. The clinical expression of MEN2 varies, although all patients develop medullary thyroid carcinoma (MTC) or its precursor C-cell hyperplasia (CCH). MEN2 can be subdivided in MEN2A, MEN2B and familial MTC (FMTC). MEN2A is characterized by MTC, pheochromocytoma (PC), and hyperparathyroidism. MEN2B is characterized by MTC, PC and mucosal ganglioneuromas (in the colon, lips and tongue). FMTC patients solely develop MTC. MTC originates from the calcitonin producing neuroendocrine C-cells in the thyroid gland, and PC originates from the neuroendocrine chromaffin cells in the adrenal medulla. 1 MEN2 patients carry an activating germ-line mutation in the RET proto-oncogene, leading to constitutive activation of its encoded transmembrane receptor tyrosine kinase RET. The MEN2 phenotype correlates strongly with specific RET mutations. 2,3 In MEN2A the mutations affect cysteine residues in the extracellular domain of the protein. The most commonly affected Cysteine is C634. 4,5 In MEN2B, the most common mutation (in 95% of the cases) results in a Methionine to Threonine substitution at position 918 in the intracellular domain of the protein. [6][7][8] Somatic RET mutations have been detected in 23-69% of sporadic MTC, the vast majority of which has the M918T mutation, as well as in 10-15% of sporadic PC, with M918T in 50% of the cases. 9 Carriers of the same germ-line RET mutation, both related and unrelated, can develop MTC and PC at widely varying ages, suggesting that in addition to the mutated RET gene, other oncogenic events are required for the development of these tumors. The most frequently detected chromosomal alteration in MTC and PC is loss of a specific part or of the entire short arm of chromosome 1. [10][11][12] The most comm...
Supplementary Figure 1 Legend from Synergistic Effect of Oncogenic <i>RET</i> and Loss of <i>p18</i> on Medullary Thyroid Carcinoma Development
Supplementary Figure 1 from Synergistic Effect of Oncogenic <i>RET</i> and Loss of <i>p18</i> on Medullary Thyroid Carcinoma Development
<div>Abstract<p>Activating mutations in the <i>RET</i> proto-oncogene are associated with both familial and sporadic medullary thyroid carcinoma (MTC) development; however, the genetic mechanisms underlying MTC tumorigenesis remain largely unknown. Recently, we have identified somatic inactivating mutations in the cell cycle inhibitor gene <i>P18</i> in human MTC, which coincided with activating <i>RET</i> mutations, suggesting a role for loss of <i>P18</i> in combination with oncogenic <i>RET</i> in the multistep process of MTC development. Therefore, we crossed transgenic mice expressing oncogenic <i>RET</i> (<i>RET2B</i>) with mice lacking <i>p18</i> (and <i>p27</i>, another cell cycle inhibitor) and monitored MTC development. <i>RET2B;p18<sup>+/−</sup></i> mice and <i>RET2B;p18<sup>−/−</sup></i> mice developed MTC with a highly increased incidence compared with their corresponding single mutant littermates. In addition, expression of oncogenic <i>RET</i> causes an earlier age of onset and larger MTCs in <i>p18<sup>−/−</sup>;p27<sup>+/−</sup></i> mice. In a subset of MTCs of <i>RET2B;p18<sup>+/−</sup>(;p27<sup>+/−</sup>)</i> mice, p18<sup>Ink4c</sup> expression was completely lost. This loss of p18<sup>Ink4c</sup> expression correlated with higher proliferation rates as well as with larger MTCs, indicating that loss of <i>p18</i> in combination with oncogenic <i>RET</i> not only increases the risk for MTC development but also enhances MTC progression. Our data strongly indicate that oncogenic <i>RET</i> and loss of <i>p18</i> cooperate in the multistep tumorigenesis of MTC. [Cancer Res 2008;68(5):1329–37]</p></div>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.